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Porcine circovirus type 2 (PCV2) vaccination represents an important measure to cope with PCV2 infection;
however, data regarding the modulation of the immune cell compartment are still limited, especially under field
conditions. This study is aimed at investigating the features of the cellular immune response in conventional piglets
induced by vaccination using a capsid (Cap) protein-based PCV2 vaccine compared to unvaccinated animals when
exposed to PCV2 natural infection. Immune reactivity was evaluated by quantifying peripheral cell subsets involved
in the anti-viral response and characterizing the interferon-gamma (IFN-γ) secreting cell (SC) responsiveness both
in vivo and upon in vitro whole PCV2 recall. The vaccination triggered an early and intense IFN-γ secreting cell
response and induced the activation of peripheral lymphocytes. The early increase of IFN-γ SC frequencies resulted
in a remarkable and transient tendency to increased IFN-γ productivity in vaccinated pigs. In vaccinated animals, soon
before the onset of infection occurred 15-16 weeks post-vaccination, the recalled PCV2-specific immune response was
characterized by moderate PCV2-specific IFN-γ secreting cell frequencies and augmented productivity together with
reactive CD4+CD8+ memory T cells. Conversely, upon infection, unvaccinated animals showed very high frequencies
of IFN-γ secreting cells and a tendency to lower productivity, which paralleled with effector CD4–CD8+ cytotoxic cell
responsiveness. The study shows that PCV2 vaccination induces a long-lasting immunity sustained by memory T
cells and IFN-γ secreting cells that potentially played a role in preventing the onset of infection; the extent and
duration of this reactivity can be an important feature for evaluating the protective immunity induced by vaccination.Introduction
Porcine circovirus type 2 (PCV2) is one of the main
pathogens responsible for relevant economic losses
worldwide; this small single-strand DNA virus belongs
to the Circoviridae family and is the causative infectious
agent, together with other viral and bacterial pathogens,
of the so-called porcine circovirus associated diseases
(PCVD) [1,2]. Several in vitro and in vivo studies have
confirmed that the virus interacts and modulates several
components of the pig immune system, having its major
tropism to the cells of the monocyte/macrophage lineage
(MØ) and dendritic cells (DC). However, it seems that
no efficient replication and spread derives from infection* Correspondence: luca.ferrari@unipr.it
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unless otherwise stated.of these susceptible immune cells, thus sustaining per-
sistent infection. In fact, PCV2 replication is dependent
on the activation and proliferation of susceptible cells
since the virus lacks its own polymerase for autonomous
propagation. It was also demonstrated that lymphocytes,
especially if activated to lymphoblasts, can carry PCV2
antigens and genome, thus representing additional target
cells. The interaction with innate immune cells and/or
with lymphocytes/lymphoblasts triggers virus replication
and subsequently immune responses in tissues; PCV2 can
also be recovered from peripheral blood mononuclear
cells (PBMC), specifically from T and B lymphocytes [3-5].
Recent studies demonstrated that the onset of humoral
immunity as total and virus-neutralizing antibodies (VNA)
upon PCV2 natural or experimental infection is an import-
ant response to counteract the onset of clinical signs. Intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cytokine production (e.g. IL-1β, IL-8, TNF-α, IL-12, IFN-γ,
IL-10) are modulated during early and late phases of infec-
tion both peripherally and locally in primary/secondary
lymphoid organs [6-17]. Diseased pigs can show the in-
crease of peripheral SWC3+ monocytes [18] or neutrophils
[19] and reduction of the leukocyte/lymphocyte population
specifically involving CD3+, CD4+, CD8+, memory T helper
(Th) CD4+CD8+ cells and CD21+/IgM+ B cells [12,18,20],
besides increased levels of IL-10 and virus-specific IL-10
secreting cells in PBMC and lymphoid organs [7,8,10,21].
Nonetheless, cellular changes are not univocal due to the
variable onset and development of the disease possibly
related to the status and age of the infected animals.
On the contrary, since PCVD is hardly induced ex-
perimentally due to the absence of triggering patho-
genic co-factors, several studies have been performed
under controlled conditions in which PCV2 infection
sustained only subclinical outcomes. In some cases,
PCV2 infection elicited an antibody response together
with virus-specific IFN-γ secreting cells constituted by
CD4+ and CD8+ cells [13,17,22-24]. In non-diseased pigs,
the changes of immune cell subsets such as T cells (naïve/
memory T helper, γ/δ T and cytotoxic T lymphocytes
(CTL)) and B cells are not intense and can be sporadic
[17,25]. However, scarce data are available during PCV2
natural infection, especially in relation to vaccination,
which surely represents one of the major measures to con-
trol PCVD. Current commercial vaccines proved to be
efficacious in reducing mortality and morbidity, and
pathological lesions, but the immune activation in-
duced systemically and at tissue level has not been
thoroughly investigated. The immune response evalu-
ated under experimental and field conditions highlighted
the involvement of both humoral and cellular immune re-
sponses in sustaining clinical protection. Specifically, stud-
ies on the efficacy of experimental/commercial vaccines in
SPF (specific pathogen-free) or conventional animals ex-
perimentally challenged after 3-6 weeks with PCV2 strains
showed the induction of virus-specific antibodies and
IFN-γ secreting cells associated with the reduction of
viremia, shedding and viral burden in tissues upon sub-
clinical outcomes [23,26-33]. A study by Seo et al. showed
that vaccination of conventional-experimentally infected
piglets using an inactivated chimeric PCV1-2 vaccine in-
duced increases of CD3+ and CD4+ cells in the blood and
sustained higher CD4+ cell levels after infection [34].
The present study is aimed at providing further insight
into the features of the cellular immune response elicited
in PCV2-vaccinated and non-vaccinated pigs naturally
infected by PCV2 at 15-16 weeks post-vaccination. The
reactivity of the immune cells was evaluated and charac-
terized in terms of changes of peripheral T immune sub-
sets, in vitro modulation of T cells upon stimulationwith PCV2 or PCV2 +mitogen and in-depth combined
quantitative and qualitative analysis of the virus-specific
IFN-γ secreting cell response.
Materials and methods
Animals and experimental design
The animals enrolled in this field study were selected in a
farrow-to-finish herd with a history of clinical signs and
mortality related to PCVD in pigs older than 15 weeks
due to a PCV2b strain.
The details about the herd health status and clinical
outcome are reported in Martelli et al. [29]. At inclusion,
the farm was seronegative for Aujeszky’s disease virus
(ADV) and seropositive for PCV2, porcine reproductive
and respiratory syndrome virus (PRRSV), Mycoplasma
hyopneumoniae (M. hyopneumoniae) and Actinobacillus
pleuropneumoniae (A. pleuropneumoniae). PCV2 sero-
positivity in sows was due to a previous infection and
not to vaccination. Some animals had antibodies against
swine influenza virus (SIV). Piglets were vaccinated for
ADV according to the National Control Program and
for M. hyopneumoniae at 1 week of age (one shot
vaccination).
At weaning (3 weeks of age), two groups of piglets
were designated as PCV2-vaccinated (PCV2-vac) group
(200 piglets) and control (C) unvaccinated group (200
piglets), respectively. Vaccination was performed intra-
muscularly (IM) by inoculating a single dose (2 mL) of a
PCV2 vaccine suspended in adjuvant to PCV2-vac pigs
while the same volume of adjuvant only was adminis-
tered to controls.
Thirty animals were selected for the study from the
PCV2-vac group (10 pigs) and C group (20 pigs). Blood
samples were collected at 3, 4, 5, 6, 7 and 9 weeks of age
(respectively 0, 1, 2, 3, 4 and 6 weeks post-vaccination
(PV)). Afterwards, the pigs were naturally exposed to
PCV2 infection by commingling them with unvaccinated
PCV2-infected animals and sampled at 15, 16, 17, 18,
19, 20, 22 and 26 weeks of age (post-exposure (PE) period).
The course of PCV2 infection (viremia in serum) was
monitored by quantitative PCR (qPCR) and the cellular
immune responsiveness was evaluated by flow cytometry
(in vivo and after in vitro PCV2 re-stimulation) and an
IFN-γ ELISPOT assay. The cellular response detected by
ELISPOT was assessed as 1) frequencies of virus-specific
IFN-γ secreting cells (SC), 2) IFN-γ responsiveness cat-
egories, 3) responsive or non-responsive animals upon
definition of a cut-off value, and 4) IFN-γ productivity
per cell in single samples and over time.
Serological analyses showed that PRRSV infection had a
seroprevalence of 100% at 12 weeks of age, concomitantly
with M. hyopneumoniae seroconversion, which increased
subsequently. Both PRRSV and M. hyopneumoniae infec-
tions tested by PCR occurred before 15-16 weeks of age
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viremia. Regarding the other above mentioned pathogens,
all pigs tested negative. The clinical signs compatible
with PCVD were mainly observed between 16 and
23 weeks PV (19-26 weeks of age). Vaccinated animals
showed significantly reduced morbidity and mortality
(0.2% vs. 9.0%) as well as a significantly higher average
daily weight gain (ADWG: +70 g/day) as compared to
controls [29].
The study was performed according to the princi-
ples of “Good Clinical Practice” and specifically, treatments,
housing, husbandry, and feeding conformed to the Euro-
pean Union (EU) Guidelines and identical for both experi-
mental groups. The protocol was approved by the Ethical
Committee for Animal Experiments of Parma University.
PCV2 vaccine, recall virus strain and field isolate
PCV2 vaccination was performed by inoculating one dose of
a commercial PCV2a-based subunit vaccine containing the
PCV2 capsid (Cap) protein expressed in a baculovirus sys-
tem (PorcilisW PCV - MSD Animal Health, Whitehouse Sta-
tion, NJ, USA) suspended in a mineral oil dl-α-tocopherol-
based adjuvant (MDF, Microsol Diluvac ForteW - MSD
Animal Health) administered intramuscularly (2 mL) in
the right neck muscle according to the manufacturer’s
recommendations.
The in vitro cell re-stimulation for flow cytometry and
ELISPOT was performed using a PCV2b virulent strain
(I12-11) isolated in 2008 from PMWS-affected pigs in
The Netherlands and propagated in PK15 cells.
The field virus infecting the animals under study
belonged to the PCV2b genotype as revealed by PCR
performed according to Horlen et al. [35].
Detection of PCV2 viremia in serum
Quantitative PCR (qPCR) was performed on serum to
establish the PCV2 status at all sampling times. PCV2
genomic DNA was extracted from 200 μL of serum
using TRIzol LS (Invitrogen, San Diego, CA, USA) and
suspended in 50 μL of diethylpyrocarbonate (DEPC)
water. PCR was performed using primers and probes ac-
cording to Olvera et al. [36] and a Light-Cycler 1.5
(Roche - Basel, CH). PCV2 titers were expressed as
PCV2 genome copies (log10)/mL.
Immunophenotyping and quantification of lymphocyte
subsets in the whole blood by flow cytometry
The immunophenotyping and quantification of lympho-
cyte subsets in the whole blood were performed by flow
cytometry as previously described [37-39]. Specifically,
cells were double-stained for surface CD3/CD8α, CD4/
CD8α, CD3/CD16, CD8β/CD25 and single stained for
TCRγ/δ. The following primary antibodies were used:
mouse anti-pig-CD3ε-PE: clone PPT3, IgG1K; mouseanti-pig-CD4α-PE: clone 74-12-4, IgG2bK; mouse anti-
pig-CD8α-FITC: clone 76-2-11, IgG2aK (Southern Biotech
Inc., Birmingham, AL, USA); mouse anti-pig-TCR1-N4
(δ-chain): cell line PGBL22A, IgG1 (VMRD Inc., Pullman,
WA, USA); mouse anti-pig-CD25 (IL-2 receptor α-chain):
clone K231.3B2, IgG1 (Serotec, Raleigh, NC, USA); mouse
anti-pig-CD8β: cell line PG164A, IgG2a (VMRD); mouse
anti-pig-CD16-FITC: clone G7, IgG1 (Serotec). TCRγ/δ
+ and
CD8β+ cell detection were achieved by a goat F(ab’)2
anti-mouse FITC-conjugated antibody (R0480; Dako
Cytomation, Glostrup, Denmark). For CD25+ cell de-
tection, a goat anti-mouse IgG1 PE-conjugate antibody
(M32001; Caltag Labs, Burlingame, CA, USA) was
used. The analysis was performed using an EpicsW XL-
MCL cytometer (Beckman-Coulter, Indianapolis, IN, USA)
based on PBMC gating after acquisition of at least 10 000
cell events and cell subsets were evaluated based on previ-
ous reports. The absolute cell levels (cells/μL) were deter-
mined based on the absolute leukocyte counts and
lymphocyte percentages [37-40].
Isolation of porcine PBMC
Porcine peripheral blood mononuclear cells (PBMC)
were isolated from blood collected in lithium-heparin by
Histopaque-1077W (Sigma, St. Louis, MO, USA) as pre-
viously described [41]. PBMC were washed and sus-
pended in complete RPMI-1640 (cRPMI) + 10% FBS
(Sigma) and viability was confirmed > 98% by Trypan
blue (Sigma). Cell samples not processed immediately
were stored in liquid nitrogen in cRPMI + 10% DMSO+
40% FBS. Upon thawing, PBMC were evaluated for viabil-
ity before being used in the immunological assays.
Characterization of the PCV2-specific lymphocyte response
in PBMC by flow cytometry upon in vitro whole virus
re-stimulation
The reactivity of lymphocyte subsets to PCV2 was char-
acterized and quantified by flow cytometry after in vitro
PCV2-specific re-stimulation. Briefly, 5 × 105 PBMC were
seeded in snap-cap tubes (Sarstedt, Nümbrecht, Germany)
and incubated for 48 h in cRPMI + 10% FBS with the
PCV2b isolate I12-11 alone (0.25 MOI) or with PCV2 +
PHA (5 μg/mL) at 37 °C, 5% CO2. PBMC were double-
stained with anti-CD4α-PE (clone 74-12-4) and anti-
CD8α-FITC (clone 76-2-11) as performed in the whole
blood. The analysis was performed after acquisition of at
least 10 000 cell events; both resting (lower scatters) and
activated PBMC (i.e. lymphoblasts, higher scatters) were
considered upon all in vitro conditions. The effective cellu-
lar responses to PCV2 or PCV2+ PHA re-stimulation were
calculated after subtracting the respective responses of cells
incubated in cRPMI-1640 + 10% FBS or with PHA alone
in cRPMI-1640 + 10% FBS respectively, and expressed as
percentage values [42].
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IFN-γ secreting cell (SC) response in PBMC
Immune cell activation was also evaluated by quantifica-
tion of the PCV2-specific IFN-γ secreting cell (SC) fre-
quencies in PBMC, according to Martelli et al. [29] with
some modifications regarding the viral re-stimulation.
Specifically, PBMC (2 × 105 cells/well) were plated in
cRPMI-1640 + 10% FBS and stimulated with the PCV2b
isolate I12-11 (range: 0.05 – 0.25 MOI) for 20 h at 37 °C,
5% CO2. The IFN-γ secreting cell number was determined
by a high-resolution CCD camera-equipped ELISPOT
reader and software v.6.0 (Autoimmun Diagnostika,
AIDW, Straßberg, Germany).
Cell incubation with PHA (10 μg/mL) and in cRPMI-
1640 + 10% FBS alone (2 × 105 PBMC/well) were per-
formed as positive and negative controls, respectively. The
spot counts in the negative controls were subtracted from
the respective counts of the stimulated cells and the im-
mune response was expressed as the number of IFN-γ se-
creting cells per million of PBMC (IFN-γ SC/106 PBMC).
In addition, the IFN-γ SC response was analyzed by
identification of IFN-γ responsiveness categories based
on the values of IFN-γ SC/106 PBMC recorded. The cat-
egories were defined as follows: 1) no-poor responders:
0-40 SC; 2) low responders: 41-100 SC; 3) intermediate
responders: 101-200 SC; 4) high responders: 201-400
SC; 5) very high responders: > 400 SC.
The ELISPOT results were also evaluated upon defin-
ition of a cut-off value of 40 IFN-γ SC/106 PBMC in
order to classify animals as responders or non-responders;
such a value was established based on the observed re-
sponses and data in the literature [23].
Based on the CCD camera images and data in the lit-
erature [41,43,44], the IFN-γ SC response was evaluated
in terms of IFN-γ productivity per cell, taking into ac-
count the spot size and intensity distributions in PCV2-
stimulated wells.
Statistical analysis
The statistical analysis for the virological, flow cytometry
and IFN-γ ELISPOT continuous data was performed by
ANOVA and Dunnett’s test in order to highlight differ-
ences between groups and over time throughout the ex-
periment. The analysis of binary (positive/negative) IFN-γ
data was performed by the Fisher’s test after determination
of a negative-to-positive cut-off value of 40 SC/106 PBMC.
All statistical analyses were performed using the SPSS pro-
gram v.17.0.1 and significance was assessed for p < 0.05.
Results
PCV2 viremia
At vaccination (3 weeks of age) and at each time point
post-vaccination, all pigs enrolled in the study tested
negative for PCV2. Virus could be detected in controlpigs only starting from 17-18 weeks up to 26 weeks of
age. PCV2 titers gradually increased peaking at 20-
22 weeks and then decreased from 22 to 26 weeks (p <
0.05). The highest individual variation in the control
group was detected at the early phase of infection (18-
19 weeks) and upon virus clearance from circulation
(26 weeks). The course of PCV2 titers in the control
group testifies that the majority of pigs was infected and
became viremic or highly viremic. Conversely, PCV2-vac
pigs were negative or had very low levels of viremia. The
PCV2 titers in controls resulted in being significantly
higher than those in the PCV2-vac group from 19 to
22 weeks of age (p < 0.05) (Figure 1).
Lymphocyte subsets in the whole blood
During the post-vaccination (PV) period, no significant dif-
ference between PCV2-vaccinated and control animals was
detected in the lymphocyte subsets investigated. However,
relevant changes were detected over time and characterized
by increases of naïve T helper lymphocytes (CD4+CD8α–
cells: 0.7 × 103 – 1.5 × 103 cells/μL), total and activated
cytotoxic T lymphocytes (CD4–CD8α+high cells: 1.6 × 103 –
2.6 × 103 cells/μL; CD8β+CD25+ cells: 25 – 80 cells/μL), cir-
culating memory T helper lymphocytes (CD4+CD8α+low
cells: 3.5 × 102 – 9.0 × 102 cells/μL) and γ/δ T lymphocytes
(TCRγ/δ+ cells: 1.4 × 103 – 2.5 × 103 cells/μL). Total
and activated NK cells (respectively, CD3–CD8α+ and
CD3–CD16+ cells) showed more stable values (1.5-
2.0 × 103 cells/μL; data not shown).
During the post-exposure (PE) period, slightly higher
levels of naïve T helper CD4+CD8α– cells were detected
in PCV2-vac pigs at weeks 19 and 20 compared to con-
trols (1.3 × 103 cells/μL vs. 1.0 × 103 cells/μL). The course
of total cytotoxic T lymphocytes (CD4–CD8α+high cells:
2.5 × 103 cells/μL) as well as of total and activated NK cells
(CD3–CD8α+ cells: 1.4 × 103 cells/μL; CD3–CD16+ cells:
1.2 × 103 cells/μL) were not influenced by PCV2 natural
infection in vaccinated and unvaccinated animals. Double
positive CD4+CD8α+low cells showed highly comparable
profiles (0.7-1.1 × 103 cells/μL) in both groups except for
higher levels in PCV2-vac pigs compared to controls on
week 22 (1.0 × 103 cells/μL vs. 0.7 × 103 cells/μL). TCRγ/
δ+ cells showed slightly higher levels in vaccinated pigs
compared to controls throughout the PE period (3.0-3.7 ×
103 cells/μL vs. 2.6-3.0 × 103 cells/μL), while CD8β+CD25+
(activated cytotoxic T lymphocytes) absolute cell numbers
showed increasing and comparable levels in the PCV2-vac
and control groups (60 – 130 cells/μL) (data not shown).
Characterization of the PCV2-specific lymphocyte response
in PBMC by flow cytometry upon in vitro whole virus
re-stimulation
During the PV period, upon PCV2 stimulation, higher levels
of both total resting PBMC (Figure 2A) and lymphoblasts
Figure 1 PCV2 viremia upon PCV2 natural infection. PCV2 genome copies (log10)/mL of serum in PCV2-vaccinated (PCV2-vac) and unvaccinated
(C) pigs in the post-exposure (PE) period to PCV2 natural infection (15-26 weeks of age) quantified by qPCR. PCV2-vac pigs were vaccinated at 3 weeks
of age using a PCV2a Cap protein-based subunit vaccine. (*): statistically significant difference between groups (p < 0.05). The cut-off value of 4 log10
(104) PCV2 genome copies/mL is assumed as the lowest limit for a productive infection.
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pigs at 4 and 6 weeks PV (p < 0.05). Upon PCV2 + PHA
stimulation, no reactivity and differences between groups
were observed in resting PBMC (Figure 2C), whereas the
fraction of activated cells characterized by higher forward
scatters was highly detectable. Such subpopulation of lym-
phoblasts showed an increase at 6 weeks PV in PCV2-vac
pigs (Figure 2D).
Overall, in vitro stimulation with PCV2 alone led to
more restricted activation and proliferation (lower per-
centages) (Figure 2B), whereas stimulation with PCV2 +
PHA induced a strong cell activation to lymphoblasts
(higher percentages) (Figure 2D).
Regarding specific T cell subsets, upon PCV2 stimula-
tion, resting total CD4+ and CD8α+ cells showed negli-
gible stimulation and no differences between groups;
CD4+CD8α– cells showed very low responsiveness which,
however, was higher in vaccinated pigs from 3 weeks PV
compared to controls (+0.5-1.5%; p < 0.05 at 3 weeks).
Resting cytotoxic CD4–CD8α+ and memory T helper
CD4+CD8α+low cells did not show significant increases
and were not statistically different between groups
(data not shown).
In the lymphoblast fraction, activated CD4–CD8α+ cells
did not show relevant differences (Figure 3A) whereas
higher reactivity was related to memory CD4+CD8α+low
T cells at 6 weeks PV (9 weeks of age) (Figure 3B).
Upon PCV2 + PHA stimulation, fluctuating values were
detected in both resting total CD4+ and CD8α+ cells (0-4%)
as well as in the specific subsets (0-2.5%); no relevant differ-
ences were found between treatment groups (data not
shown).In the PV period, activated total CD4+ and CD4+CD8α–
cells showed comparable responsiveness in both groups
whereas CD8α+ cells were higher (+3%) in PCV2-vac pigs
at 9 weeks of age (6 weeks PV). High individual variation
characterized activated CD4–CD8α+ cells in both groups
so that the profiles were comparable, despite a higher
mean value in the PCV2-vac group at 9 weeks of age
(Figure 3C). Memory CD4+CD8α+low cells were slightly
higher in the PCV2-vac group from 2 to 4 weeks PV
(5-7 weeks of age; p < 0.05 at 2 weeks PV) (Figure 3D).
During the post-exposure period, upon PCV2 stimula-
tion, resting PBMC were higher in vaccinated pigs from
week 15 to week 18 compared to controls (+0.5-4%);
however, the resting lymphocyte specific subsets were
not significantly influenced (data not shown).
Interestingly, despite both groups showing comparable
courses of lymphoblast counts, total CD4+ and CD8α+
cell reactivity was higher in PCV2-vac pigs during the
first weeks PE before PCV2 infection occurred (16-
17 weeks of age). Specifically, CD4+CD8α– naïve T helper
cells and especially memory T helper CD4+CD8α+low cells
were responsible for such different cell reactivity. The in-
crease of total CD8α+ cell reactivity from 18-19 weeks of
age onwards was concomitant with the response of the
cytotoxic CD4–CD8α+ subset, which resulted in being
more intense in unvaccinated infected pigs (Figure 4).
During the PE period, upon PCV2 + PHA stimulation,
resting PBMC did not show any significant changes over
time and between groups; resting total CD4+ and CD8α+
cells showed a responsiveness of 0-1% and 2-7%, respect-
ively. Activated PBMC increased over time (0.5% – 3%) in
both groups and showed comparable levels; the changes
Figure 2 Total resting PBMC and lymphoblasts upon in vitro stimulation after Cap protein PCV2 vaccination. Cell levels of resting and
activated PBMC in PCV2-vaccinated (PCV2-vac) and control (C) pigs upon 48-h PCV2b (A, B) and PCV2b + PHA (C, D) in vitro stimulation during
the post-vaccination (PV) period. Values are normalized to the corresponding medium (PCV2 stimulation) and PHA-alone (PCV2 + PHA stimulation)
control samples, respectively. PCV2-vac pigs were vaccinated at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine. (*): statistically
significant difference between groups (p < 0.05).
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CD4–CD8α+ cells during the first 2-3 weeks (0-4%). React-
ive CD4+ cells were composed of activated CD4+CD8α–
cells both in PCV2-vac and control pigs (data not shown).
PCV2-specific IFN-γ secreting cell (SC) response in PBMC
During the post-vaccination (PV) period, the response
quantified as frequencies of IFN-γ SC highlighted that
immune responsiveness was elicited in PCV2-vac pigs
early after vaccine inoculation; a statistically different re-
sponse between PCV2-vac and control animals was ob-
served from 2 weeks PV (5 weeks of age) onwards, up to
6 weeks PV (9 weeks of age) (p < 0.05). However, some
pigs categorized as low (41-100 SC) and intermediate
(101-200 SC) responders showed a detectable response
already at 1 week PV. The response was negligible in
controls throughout the PV period (data not shown).
Specifically, since PCV2-vac pigs showed high individual
variation, several IFN-γ responsiveness categories were iden-
tified. Before vaccination, all vaccinated animals showedfrequencies of 0-40 IFN-γ SC/106 PBMC identifying no-
poor responders, whereas pigs showing a response of
41-200 IFN-γ SC/106 PBMC were detected already at
1 week PV. The maximum response was observed be-
tween 2 and 6 weeks PV and was characterized by a
major fraction of high (201-400 IFN-γ SC/106 PBMC)
and very high (> 400 IFN-γ SC/106 PBMC) responder
animals. The control pigs were distributed in the no-
poor response category throughout the PV period.
The analysis of the ELISPOT response based on the def-
inition of a cut-off value of 40 IFN-γ SC/106 PBMC allowed
determining a statistically significant response from 1 week
PV (2/10 vs. 0/10 positive pigs; p < 0.05) onwards in PCV2-
vac pigs compared to controls. In particular, the majority of
vaccinated pigs showed a significant response between 2
(8/10) and 3 (9/10) weeks PV (p < 0.05). The SC response
upon cut-off determination showed the same trend as upon
analysis of mean values (data not shown).
During the post-exposure (PE) period, the IFN-γ SC
response in PCV2-vac pigs was higher than in controls
Figure 3 Cellular immune reactivity of activated T lymphocyte subsets upon in vitro stimulation after Cap protein PCV2 vaccination.
Levels of CD4–CD8α+ cytotoxic and CD4+CD8α+low memory T helper cells in the lymphoblast fraction of PCV2-vaccinated (PCV2-vac) and control
(C) pigs upon 48-h PCV2b (A, B) and PCV2b + PHA (C, D) in vitro stimulation during the post-vaccination (PV) period. PCV2-vac pigs were vaccinated
at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine. Values are normalized to the corresponding medium (PCV2 stimulation)
or PHA-alone (PCV2 + PHA stimulation) control samples, respectively. (*): statistically significant difference between groups (p < 0.05).
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60-70 IFN-γ SC/106 PBMC. During these weeks, the
control group showed mean frequencies of 30-40 IFN-γ
SC/106 PBMC. Afterwards, the levels in controls signifi-
cantly increased and reached higher levels from week 5
to week 11 PE (20-26 weeks of age; p < 0.05). Vaccinated
pigs showed a significant temporary increase on week 7
PE (22 weeks of age; p < 0.05) (Figure 5).
The analysis performed by IFN-γ responsiveness cat-
egories highlighted that the most represented fraction in
vaccinated animals was characterized by relatively low
responders (41-100 IFN-γ SC/106 PBMC) at almost all
time points. A minor fraction of intermediate (101-200
IFN-γ SC/106 PBMC) and high (201-400 IFN-γ SC/106
PBMC) responders was also detected both early (10%)
and late (20-30%) after exposure, respectively (Figure 6A).
Conversely, in control pigs, the category distribution
drastically changed after the onset of infection in favor
of large fractions of high and very high responders after
18 weeks of age. At 22-26 weeks of age, no/poor re-
sponders were not detected in controls and fractionsranging from 10% to 50% of very high responders were
found (Figure 6B).
ELISPOT data analyzed using the cut-off value showed
that the PCV2-vac group had a significantly higher frac-
tion of responding pigs before the onset of PCV2
viremia (15-18 weeks of age) ranging between 60% and
100% compared to controls (p < 0.05), whereas unvaccin-
ated pigs had no relevant response at 15 weeks of age
and only a minor fraction of responding animals be-
tween 16 and 18 weeks of age (25% and 35%). Upon infec-
tion, controls showed a relevant increase of responsiveness
up to 100% at 22-26 weeks of age while PCV2-vac pigs
ranged between 50% and 80% (p < 0.05) (Figure 7).
The IFN-γ SC response was additionally evaluated as
IFN-γ productivity per cell depending on the amount of
IFN-γ secreted by a single cell.
During the PV period, the early responding pigs (re-
sponse at 1 week PV) were characterized by low frequen-
cies of IFN-γ SC generally associated with low secretion
per cell, which means small and/or low intensity spots in-
dependently from the PCV2 amount used as recall antigen.
Figure 4 Cellular immune reactivity of activated T lymphocyte subsets upon in vitro stimulation after PCV2 natural exposure. Levels of
CD4+ and CD8α+ cell subsets in PCV2-vaccinated (PCV2-vac) and control (C) pigs during the post-exposure (PE) period upon 48-h PCV2b in vitro
stimulation. PCV2-vac pigs were vaccinated at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine. Values are normalized to the
corresponding medium control samples. (*): statistically significant difference between groups (p < 0.05).
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http://www.veterinaryresearch.org/content/45/1/44The in-depth visual monitoring of the post-vaccination
responses allowed detecting differential behaviors in
PCV2-vac pigs. At 2 weeks PV, some animals showedhigher frequencies of IFN-γ SC characterized by much
higher IFN-γ productivity per cell (Figures 8A and B). In
addition, some samples showed a strong heterogeneity
Figure 5 Frequencies of PCV2-specific IFN-γ secreting cells (SC) upon PCV2 natural exposure. Levels of IFN-γ SC in PBMC of PCV2-vaccinated
(PCV2-vac) and unvaccinated (C) pigs in the post-exposure (PE) period. The magnified graph highlights the profiles of the two groups before the onset
of significant PCV2 viremia in the PE period. PCV2-vac pigs were vaccinated at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine. PBMC
were ex vivo re-stimulated for 20 h with 0.25 MOI of a whole PCV2b strain. (*): statistically significant difference between groups (p < 0.05).
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http://www.veterinaryresearch.org/content/45/1/44of IFN-γ productivity at a specific time point and a shift
from higher to lower productivity associated with in-
creased frequencies between 2 and 3 weeks PV (Figures 8C
and D).
The evaluation of the IFN-γ productivity during the
PE period, and specifically after PCV2 natural infection,
highlighted different features when comparing PCV2-vac
and control pigs: 1) in some PCV2-vac animals, a lower
IFN-γ SC response was characterized by a stable cell fre-
quency and increase of IFN-γ productivity depending on
the recall PCV2 antigen amount (Figure 9A); 2) in some
control animals, a much higher SC response was charac-
terized by an increasing cell frequency and stably lower
IFN-γ productivity depending on the recall PCV2 anti-
gen amount (Figure 9B).
Discussion
The study was performed in maternally-immune piglets
intramuscularly vaccinated for PCV2 by administration
of a Cap-based subunit vaccine and in unvaccinatedanimals, subsequently exposed to PCV2 natural infec-
tion. The high degree of protection against severe PCVD
clinical signs observed after infection in vaccinated pigs
was demonstrated by the significant reduction of morbid-
ity and mortality associated with PCV2 positivity and
PCVD-compatible lesions as well as by the improvement
of the ADWG [29].
The changes observed over time during the PV
period in both groups related to the CD4+ T helper
(naïve CD4+CD8α– and memory CD4+CD8α+low) and
total/activated CD8+ cytotoxic (CD4–CD8α+high, TCRγ/δ+,
CD8β+CD25+) subsets can be attributed to the physio-
logical development of the immune competence in grow-
ing piglets [37].
The exposure to PCV2 natural infection was evident
both as high viremia levels and PCVD clinical signs from
19 weeks of age in unvaccinated animals. During the
PE period, the slightly but not significantly higher
levels of CD4+CD8α– T helper cells and γ/δ T lympho-
cytes in the PCV2-vac group were attributed to changes
Figure 6 PCV2-specific IFN-γ responsiveness categories upon PCV2 natural exposure. Category distribution in PBMC of (A) PCV2-vaccinated
(PCV2-vac) and (B) unvaccinated control (C) pigs in the post-exposure (PE) period to PCV2 natural infection (15-26 weeks of age). PCV2-vac pigs
were vaccinated at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine. PBMC were ex vivo re-stimulated for 20 h with 0.25 MOI of
a whole PCV2b strain.
Figure 7 PCV2-specific ELISPOT positivity upon PCV2 natural exposure. Percentages of responsive animals evaluated upon definition of a
cut-off value of 40 IFN-γ SC/106 PBMC in PCV2-vaccinated (PCV2-vac) and unvaccinated (C) pigs in the post-exposure (PE) period to PCV2 natural
infection (15-26 weeks of age). PCV2-vac pigs were vaccinated at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine. PBMC were
ex vivo re-stimulated for 20 h with 0.25 MOI of a whole PCV2b strain. (*): statistically significant difference between groups (p < 0.05).
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Figure 8 Differential IFN-γ productivity after Cap protein PCV2 vaccination. Comparison of two representative samples of PCV2-vaccinated
pigs characterized by higher (A) and lower (B) PCV2-specific IFN-γ productivity per cell, that is larger and smaller spot sizes depending on the
amount of IFN-γ secreted by ex vivo PCV2-stimulated cells. The responses shown were observed at 2 weeks after PCV2 vaccination (PV) upon
re-stimulation with a PCV2b strain (0.25 MOI). A representative transient increase of IFN-γ productivity per cell is shown in a PCV2-vaccinated
pig at 2 weeks (C) and 3 weeks (D) PV. The numbers are relative to the spots counted in the stimulated well shown (2 × 105 PBMC) and (in
brackets) the mean of the corresponding unstimulated negative control wells (2 × 105 PBMC). The spot size and spot intensity distributions
are shown as histogram plots on a linear scale. PCV2-vac pigs were vaccinated at 3 weeks of age using a PCV2a Cap protein-based
subunit vaccine.
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Figure 9 Differential PCV2-specific IFN-γ secretion responses upon PCV2 natural exposure. Representative responses of one PCV2-vaccinated
(A) and one unvaccinated (B) pig at 19 weeks of age (+4 weeks post-exposure (PE) to PCV2 natural infection) characterized respectively by stable IFN-γ
SC number and increased/higher IFN-γ productivity per cell (A) or increased cell number and stable/lower IFN-γ productivity per cell (B) depending
on the amount of PCV2b used as ex vivo recall antigen. The numbers are relative to the spots counted in the stimulated well shown (2 × 105
PBMC) and (in brackets) the mean of the corresponding unstimulated negative control wells (2 × 105 PBMC). The spot size and spot intensity
distributions are shown on a linear scale. PCV2-vac pigs were vaccinated at 3 weeks of age using a PCV2a Cap protein-based subunit vaccine.
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study, PCVD was not associated with a significant modu-
lation of these peripheral cell subsets involved in sustain-
ing the Th1-biased anti-viral immunity upon infection.
This can be due to the different extent of negative im-
mune modulation induced by PCV2 in infected pigs de-
pending on different field conditions [12,18-20,25].
Conversely, the involvement of both CD4+ and CD8+
cells in terms of lymphoproliferative response upon
PCV2 infection appeared to be important to evaluate, as
previously demonstrated under experimental conditions
[45]. The cellular responsiveness to PCV2 antigen was
evaluated upon in vitro stimulation of PBMC with whole
PCV2 alone or in the presence of PHA as a mitogenic
stimulating factor, since it is known that mitogens can
synergistically up-regulate several cell responses to
PCV2 due to their IFN-α/IFN-γ-dependent lymphopro-
liferative effects [4,5,46,47].
Post-vaccination data showed that the PCV2 in vitro
recall had a stimulatory effect on both resting PBMC
and PBMC activated to lymphoblasts at 4-6 weeks PV,
suggesting a delayed and not intense induction of im-
mune cells able to respond when stimulated by the viral
antigen. This responsiveness seemed to be sustained by
CD4+ cells, specifically T helper naïve CD4+CD8α– and
memory CD4+CD8α+low cells. The recall of memory cells
is particularly important since this subset is involved in
the regulation of the anti-viral response by IFN-γ secre-
tion and virus clearance when infection occurs [40].
The addition of PHA induced higher levels of respond-
ing cells in the activated fraction only, suggesting a detect-
able influence on proliferating previously primed cells of
vaccinated animals. These in vitro conditions highlighted
higher CD4–CD8α+ cells at 6 weeks PV, thus also pointing
out a possible involvement of cytotoxic cells.
It is noteworthy that the absence of significant differ-
ences or erratic responses during the early time points
after vaccination could have been influenced by the abil-
ity of the whole virus used as in vitro recall antigen to
induce inhibition of immune responsiveness that coun-
teracted cell activation [8,33,48].
During the PE period, the levels of activated CD4+ and
CD8α+ cells in vaccinated pigs were significantly higher
than in controls during the first weeks before infection
(15-17 weeks); these subsets were mainly constituted of
naïve and memory T helper cells able to respond toPCV2. In vaccinated animals, memory cells can be in-
volved in efficiently coping with infection and preventing
the disease. It is well known that memory lymphocytes
produce IFN-γ, thus driving the Th1 response, activating
cytotoxic effector cells to eliminate infected cells, and
promoting virus-specific antibody production [40].
In fact, in vaccinated pigs, the onset of PCV2 infection
was promptly counteracted so that a significant viremia
was detected in one pig only at one time point (105 PCV2
genome copies/mL). High variation was observed in cell
counts in both groups, suggesting that the in vitro inter-
action with the virus is variable since both monocytes and
lymphocytes can be differentially infected [3,4,47,49].
The in vitro inhibitory effect of whole PCV2 stimula-
tion seemed to be evident in unvaccinated animals at
the time points preceding infection since negative per-
centage values represent lower values in the stimulated
samples compared to unstimulated PBMC used as corre-
sponding internal controls. In control animals, upon es-
tablishment of infection (19-26 weeks), higher percentages
of CD8α+ and CD4–CD8α+ cells in the absence of signifi-
cantly higher values of memory CD4+CD8+low cells dem-
onstrate that total CD8+ cells were mainly constituted by
cytotoxic effector cells (likely NK cells, γ/δ Tand cytotoxic
T lymphocytes) which were not previously primed.
PCV2 vaccination elicited an early and significant
IFN-γ SC response; the significant response was con-
firmed by cut-off analysis in agreement with previous
data by Pérez-Martín et al. [23]. The early responding
pigs showed low IFN-γ productivity per cell (spot size
and intensity depending on the amount of cytokine se-
creted by single cell) suggesting that this early respon-
siveness was associated with low secretion T cells.
The response strongly increased during the following
weeks, reaching average frequencies of 200 SC/106 PBMC
due to very high responder pigs, differently from what was
observed under experimental conditions with conven-
tional and SPF piglets [17,23], testifying that vaccination
induced a very strong response in conventional pigs. The
response could be properly detected using a PCV2b iso-
late as in vitro recall antigen in PCV2a Cap-based vacci-
nated pigs; this further supports cross-reactivity in antigen
recognition between different genotypes [24,33].
This study first demonstrates that a marked increase
of IFN-γ productivity per cell concomitant with the in-
crease of IFN-γ SC frequency is a mechanism observed
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based subunit vaccine similarly to what is documented
with vaccinia-virus in humans [43]. Since these highly
productive cells are often considered to be the most pro-
tective, this is an important feature and marker to evalu-
ate by ELISPOT. This behavior was transient as in
humans, not being evident in cells from vaccinated ani-
mals at 3 weeks of age; also in conventional pigs, this
suggests that increased productivity is related to recent
in vivo T cell activation rather than being a stable condition.
The increase of IFN-γ productivity detected in some vac-
cinated pigs after infection strengthens what was observed
after vaccination and may represent an important mechan-
ism sustaining the efficiency of the immune response.
Before infection (15-18 weeks), PCV2-vac pigs showed
significantly higher SC levels than controls. The minor
fraction of responsive pigs in the unvaccinated group may
be due to an earlier infection in some animals, although
unspecific responses cannot be completely ruled out.
In PCV2-vac pigs, the parallel higher frequencies of
IFN-γ secreting cells and percentages of virus-specific
CD4+CD8+low T cells at 15-18 weeks suggest that vaccin-
ation sustained long-lasting immune memory cells that
are able to proliferate and potentially responsible for
IFN-γ secretion upon re-exposure to the PCV2 antigen.
When infection and clinical signs occurred, unvaccinated
pigs showed a significant increase of IFN-γ SC frequencies,
with the highest fraction of very high responders (> 400
SC) at 2 weeks post-infection. This study highlights that in
the field, on the contrary to what was observed under con-
trolled conditions [17,23], a wide distribution in all the re-
sponsiveness categories was found in control pigs
testifying the extremely variable response to primary
PCV2 infection, especially during the first weeks of
infection.
In control pigs, IFN-γ secreting cells increased simul-
taneously with CD4–CD8α+ effector cells, as reported
under experimental conditions (SPF piglets, asymptom-
atic infection [13]). Moreover, the spread of infection
and onset of clinical signs in control pigs support the hy-
pothesis of an altered immune responsiveness, since the
high levels of IFN-γ SC did not associate with efficient
viral clearance; this latter condition could be related to a
negative immunomodulation by the induction of IL-10,
as previously reported in severely diseased animals [10].
Vaccinated pigs showed a lower and more homoge-
neous response characterized by a large fraction belong-
ing to the low/intermediate responsiveness categories as
observed under similar field conditions [30]. As dis-
cussed above, an important feature observed during in-
fection was that the lower IFN-γ SC response in some
vaccinated animals compared to the high response in
the majority of unvaccinated pigs was associated with in-
creased productivity per cell instead of increased cellfrequency. This feature is worth being further investi-
gated since no clear association between post-vaccination
and/or post-infection IFN-γ productivity and protection
was found.
In conclusion, under the conditions of this study, the
administration of a PCV2 subunit vaccine induced a
long-lasting immunity sustained by reactive CD4+CD8+
memory T cells and IFN-γ secreting cells, which were
associated with the prevention or reduction of infection
and clinical signs. The extent and duration of this cellu-
lar reactivity can be fundamental to drive an efficient
Th1-biased biased response to infection, thus represent-
ing an important feature for the evaluation of immune
protection induced by vaccination in the field.
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